(Total Views: 637)
Posted On: 06/09/2022 4:34:41 PM
Post# of 155753
I posted on both boards because I didn't see anyone else posting it and the page had changed since I last visited the site.
As for being new or not, this is the first time I saw any mention of the results for 700mg. In January we had PRs related to the open label 350mg but were wondering what happened to the 700mg. This appears to at least summarize those results.
Look at the metadata for the document and you will note that it has a modified date of 6/8/2022. To me, that suggests that there is validity to think it is new. But if you find otherwise, happy to have mods delete my post. Really no agenda here other than to share what I found. GLTU!
As for being new or not, this is the first time I saw any mention of the results for 700mg. In January we had PRs related to the open label 350mg but were wondering what happened to the 700mg. This appears to at least summarize those results.
Look at the metadata for the document and you will note that it has a modified date of 6/8/2022. To me, that suggests that there is validity to think it is new. But if you find otherwise, happy to have mods delete my post. Really no agenda here other than to share what I found. GLTU!
Quote:
Title: Efficacy and safety of leronlimab in patients with nonalcoholic steatohepatitis: topline results of NASH01 clinical trial
Author: Dr. Christopher Recknor
Subject: Efficacy and safety of leronlimab in patients with nonalcoholic steatohepatitis: topline results of NASH01 clinical trial
Keywords: -
Created: 9/24/21, 10:35:00 AM
Modified: 6/8/22, 5:23:36 AM
Application: Aspose Ltd.
(9)
(0)
